Recent Leukemia News

FDA Grants Accelerated Approval to Bosulif for Treatment of Newly-Diagnosed Chronic Myelogenous Leukemia (January 14, 2018)

CancerConnect News: On December 19, 2017, the Food and Drug Administration granted accelerated approval to bosutinib Bosulif (bosutinib) for treatment of patients with newly-diagnosed chronic phase (CP)... Continue Reading

Pass it On: It’s Leukemia National Awareness Month (September 19, 2017)

Leukemia and lymphoma are both hematologic malignancies, meaning that they involve the blood or bone marrow. The American Cancer Society (ACS) estimates that there will be 60,140 new cases of leukemia... Continue Reading

FDA Approves Mylotarg for Treatment of Acute Myeloid Leukemia (September 5, 2017)

The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive... Continue Reading

FDA Approves First Gene Therapy (September 1, 2017)

CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia The U.S. Food and Drug Administration issued a historic action today making the first gene... Continue Reading

FDA Approves First Gene Therapy (September 1, 2017)

CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia The U.S. Food and Drug Administration issued a historic action today making the first gene... Continue Reading

The US Food and Drug Administration has approved Besponsa for the Treatment of Refractory B-cell Precursor Acute Lymphoblastic Leukemia (August 22, 2017)

Besponsa (Inotuzumab ozogamicin) is a targeted therapy designed to bind to B-cell acute lymphoblastic leukemia (ALL) cancer cells that express the CD22 antigen. Acute lymphoblastic leukemia comprises approximately... Continue Reading

FDA Approves IDHIFA A new Targeted Treatment for Acute Myeloid Leukemia (August 10, 2017)

The U.S. Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation.... Continue Reading

Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL (July 12, 2017)

Recommendation based on review of CTL019 r/r B-cell ALL development program, including the pivotal Phase II global ELIANA trial  A Biologics License Application (BLA) for this indication is under FDA... Continue Reading

Precision Therapy Enasidenib Effective in Treating Acute Myeloid Leukemia (June 20, 2017)

According to early clinical trial results published in the journal Blood, some patients with relapsed or treatment-resistant acute myeloid leukemia may achieve remission with an experimental targeted therapy. AML... Continue Reading

Sprycel Effective for Treatment of Pediatric Chronic Myeloid Leukemia (June 14, 2017)

In 2002, the FDA approved the drug Gleevec (imatinib) as a first-line therapy for adults with chronic myeloid leukemia (CML) caused by the fusion gene BCR-ABL, known as the Philadelphia chromosome. The... Continue Reading

Next Page »